Cantor Fitzgerald Estimates ADMA Biologics FY2026 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for ADMA Biologics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of $1.02 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. ADMA Biologics’s revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 earnings per share.

Other equities analysts also recently issued reports about the company. Raymond James boosted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $20.86 on Tuesday. The company has a market capitalization of $4.98 billion, a PE ratio of 74.50 and a beta of 0.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The business’s fifty day moving average is $20.74 and its 200 day moving average is $18.86. ADMA Biologics has a fifty-two week low of $10.21 and a fifty-two week high of $25.67.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter worth about $19,076,000. Allspring Global Investments Holdings LLC lifted its position in shares of ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares in the last quarter. Nkcfo LLC purchased a new stake in shares of ADMA Biologics in the fourth quarter worth about $325,000. JPMorgan Chase & Co. lifted its position in shares of ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company’s stock worth $13,159,000 after buying an additional 561,310 shares in the last quarter. Finally, Navellier & Associates Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter worth about $3,065,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director now owns 478,194 shares in the company, valued at $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 7,779 shares of the business’s stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the sale, the director now owns 114,830 shares in the company, valued at $2,333,345.60. This represents a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 19,000 shares of company stock worth $395,736 over the last quarter. Insiders own 3.50% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.